Companies in #Alcohol Use Disorder

DemeRx is a clinical-stage biopharmaceutical company developing ibogaine-derived therapeutics for substance use disorders and other CNS conditions. Its lead candidate DMX-1001 is an oral noribogaine formulation designed to retain the anti-addiction properties of ibogaine while improving cardiac safety and pharmacokinetic control. The company is launching the first U.S. clinical trial of an ibogaine-derived candidate, advancing a long-controversial psychedelic mechanism into modern clinical development.